Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ERhS 2025

European Rhinologic Society (ERhS) - 2025

June 22 - 25, 2025

    1. All
    2. TEZSPIRE (tezepelumab)

    HTML

    Efficacy and safety of tezepelumab in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps: results from the phase 3 WAYPOINT study

    PDF

    Efficacy of tezepelumab on loss of smell in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps in the phase 3 WAYPOINT study

    PDF

    Estimating meaningful change thresholds for the Nasal Polyposis Symptom Diary: analysis of the WAYPOINT trial

    PDF

    Onset of action of tezepelumab in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps in the phase 3 WAYPOINT study

    HTML

    Response to tezepelumab treatment among adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps: results from the phase 3 WAYPOINT study

     

    HTML

    Efficacy and safety of tezepelumab in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps: results from the phase 3 WAYPOINT study

    PDF

    Efficacy of tezepelumab on loss of smell in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps in the phase 3 WAYPOINT study

    PDF

    Estimating meaningful change thresholds for the Nasal Polyposis Symptom Diary: analysis of the WAYPOINT trial

    PDF

    Onset of action of tezepelumab in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps in the phase 3 WAYPOINT study

    HTML

    Response to tezepelumab treatment among adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps: results from the phase 3 WAYPOINT study

     

    Disclaimer

    Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

    Connessiallasalute.it

    This site is intended for healthcare professionals practicing in the US.
    ©2026 AstraZeneca. All rights reserved.

    US-107328
    Last Updated 5/26

    Contact Us

    About Us

    AstraZeneca-US.com

    Grant Opportunities  

    Survey Feedback

    Your Privacy Choice

    Consumer Health Data
    Privacy Notice

    Privacy Notice | Legal Notice | Cookie Preferences

    Welcome to AstraZeneca Medical Information

    The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

     

    This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

     

    Are you a healthcare professional practicing in the United States?

    I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
    This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
    I am not a healthcare professional practicing in the United States